Provexis plc (AIM:PXS)
London
· Delayed Price · Currency is GBP · Price in GBX 0.6250
0.00 (0.00%)
At close: Dec 5, 2025
Provexis Revenue
In the fiscal year ending March 31, 2025, Provexis had annual revenue of 1.29M GBP with 61.13% growth. Provexis had revenue of 506.90K in the half year ending March 31, 2025, with 140.75% growth.
Revenue
1.29M
Revenue Growth
+61.13%
P/S Ratio
11.35
Revenue / Employee
430.75K
Employees
3
Market Cap
14.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.29M | 490.28K | 61.13% |
| Mar 31, 2024 | 801.96K | 412.05K | 105.68% |
| Mar 31, 2023 | 389.92K | -36.25K | -8.51% |
| Mar 31, 2022 | 426.17K | -79.16K | -15.67% |
| Mar 31, 2021 | 505.33K | 157.39K | 45.24% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Convatec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Genus | 672.80M |
Provexis News
- 16 days ago - AIM Market Roundup: Provexis, Geo Exploration, Sabien - The Armchair Trader